RedHill Biopharma's Opaganib Demonstrates Significant Decrease... - 07 September 2021 21:00

TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire-AsiaNet/ -- - COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chroni...

  Keen Eye launches its next-gen platform to accelerate clinical... - 07 September 2021 21:00

PARIS, Sept. 7, 2021 /PRNewswire-AsiaNet/ -- It enables every actor in Pathology to run digital image analysis in the context of clinical trials, as in CAP/CLIA laboratories, with unprecedented efficiency. This AI-platform strengthens Keen Eye's strategic positioning in the clinical research...

  RedHill Biopharma Presents Three New Analyses of Movantik Data... - 07 September 2021 20:22

TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire-AsiaNet/ -- - Two new analyses of Movantik(R) (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged >/=65 years - Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete sponta...

  Jubilant Biosys Limited announces the appointment of Mr. Giuli... - 07 September 2021 18:53

BENGALURU, India, Sept. 7,2021/PRNewswire-AsiaNet/-- Today, Jubilant Biosys Limited announced the appointment of Giuliano Perfetti as its Chief Executive Officer. Mr. Perfetti has more than 20 years of experience across diverse businesses and global markets with expertise in Strategy, Sa...

  MIM Software Inc. Announces AI Segmentation and Single Timepoi... - 07 September 2021 17:00

CLEVELAND, Sept. 7, 2021 /PRNewswire-AsiaNet/ -- MIM Software Inc., a leading global provider of medical imaging software, announced today new innovations to MIM SurePlan(TM) MRT, its software package for Molecular Radiotherapy. Logo - https://mma.prnewswire.com/media/709760/MIM_Software_Logo...

  JW Therapeutics Announces NMPA Approval of Relmacabtagene Auto... - 06 September 2021 21:59

SHANGHAI, Sept. 6, 2021/PRNewswire-AsiaNet/ -- - The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally - Currently the only approved CAR-T product that has been simultaneously included in the Nat...

  Clinical trial provides preliminary evidence of a cure for mya... - 03 September 2021 08:00

BURLINGAME, Calif., Sept. 3, 2021 /PRNewswire-AsiaNet/ -- Cortene Inc. announces publication of its InTiME clinical trial in which a short subcutaneous infusion of its experimental drug, CT38, achieved sustained symptom improvement in ME/CFS. The company intends to test CT38 in Long Covid, the post-acut...

  Angel Yeast Launches Patented Saccharomyces Boulardii Bld-3, a... - 03 September 2021 01:44

YICHANG, China, Sept. 2, 2021 /PRNewswire-Asianet/ -- Angel Yeast Co., Ltd (http://en.angelyeast.com/)("Angel Yeast" or "Angel"), a listed high-tech yeast company in China, announced its nutritional R&D team has developed a new strain of yeast probiotic, Saccharomyces boulardii Bld-3 (S. boulardii Bl...

  SynForU(TM)-HerCare probiotics shows benefits to reduce vagina... - 01 September 2021 11:00

KAOHSIUNG,Taiwan,Sept.1,2021/PRNewswire-AsiaNet/-- The first clinical study which has been published in the Journal of Applied Microbiology documents that SynForU(TM)-HerCare is effective in reducing vulvovaginal symptoms and recurrences of vaginal candidiasis (VC) in pregnant women. SynForU(T...

  European Stroke Organisation Conference (ESOC) 2021: Non-tradi... - 01 September 2021 08:00

BASEL, Switzerland, Sept. 1, 2021 /PRNewswire-AsiaNet/-- Work stress, sleep disorders, and fatigue, regarded as non-traditional risk factors for heart attack and stroke, are rising more steeply amongst women than men, according to a new study presented today at the European Stroke Organisation (ESO) Con...